Research programme: Zika virus infection vaccine - CaroGen Corporation
Latest Information Update: 13 Sep 2023
At a glance
- Originator CaroGen
- Developer CaroGen; University of Connecticut
- Class Synthetic vaccines; Zika virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Zika virus infection
Most Recent Events
- 13 Sep 2023 Discontinued - Preclinical for Zika virus infection (Prevention) in USA (unspecified route)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Zika-virus-infection(Prevention) in USA
- 03 Aug 2016 Preclinical trials in Zika virus infection (Prevention) in USA (unspecified route)
Development Overview
Introduction
CaroGen Corporation was developing a first-in-class nanoparticle vaccine for the prevention of Zika virus infection, using the virus-like vesicle (VLV) platform technology developed at Yale University School of Medicine. The VLV technology is a hybrid combination of components from the alphavirus Semliki Forest virus (SFV) and rhabdovirus vesicular stomatitis virus (VSV). Preclinical development was underway in the US. However, as at September 2023, Zika virus infection vaccine was no longer listed on the company pipeline, therefore, it appears that development has been discontinued for Zika virus infection in the US (CaroGen, September 2023)
Key Development Milestones
As at September 2023, Zika virus infection vaccine was no longer listed on the company pipeline, therefore, it appears that development has been discontinued for Zika virus infection in the US (CaroGen, September 2023)
CaroGen was collaborating with the Center for Excellence for Vaccine Research (CEVR) at the University of Connecticut in the development of its Zika virus infection vaccine.
Drug Properties & Chemical Synopsis
- Formulation unspecified
- Class Synthetic vaccines, Zika virus vaccines
- Mechanism of Action Immunostimulants
-
WHO ATC code
J07B-X (Other viral vaccines)
-
EPhMRA code
J7E9 (All other viral vaccines)
Development Status
Summary Table
| Indication | Qualifier | Patient Segment | Phase | Countries | Route / Formulation | Developers | Event Date |
|---|---|---|---|---|---|---|---|
| Zika virus infection | - | Prevention | Discontinued (Preclinical) | USA | unspecified / unspecified | CaroGen, University of Connecticut | 13 Sep 2023 |
Commercial Information
Involved Organisations
| Organisation | Involvement | Countries |
|---|---|---|
| CaroGen | Originator | USA |
| CaroGen | Owner | USA |
| Yale University School of Medicine | Technology Provider | USA |
| University of Connecticut | Collaborator | USA |
Development History
| Event Date | Update Type | Comment |
|---|---|---|
| 13 Sep 2023 | Phase Change - Discontinued(Preclinical) | Discontinued - Preclinical for Zika virus infection (Prevention) in USA (unspecified route) Updated 13 Sep 2023 |
| 28 Sep 2020 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Zika-virus-infection(Prevention) in USA Updated 28 Sep 2020 |
| 03 Aug 2016 | Phase Change - Preclinical | Preclinical trials in Zika virus infection (Prevention) in USA (unspecified route) Updated 03 Aug 2016 |
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG